Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Biopreserv Biobank ; 20(1): 97-103, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34962137

ABSTRACT

Introduction: The transportation of tissues from hospitals to clinical laboratories for cell therapy is an essential component of regenerative medicine. Previously, we used laboratory-cultured mucosal cells from buccal epithelium expanded and encapsulated using a scaffold-hybrid approach to the urethral stricture (BEES-HAUS) procedure. In this study, to improve the outcomes, we compared the thermoreversible gelation polymer (TGP) transportation procedure with conventional culture methods, and reported its advantages. Methods: Human buccal mucosal tissues in Phase I of the study were transported in Euro-Collins solution (ECS) and the cells obtained were cultured in two-dimensional (2D) Dulbecco's modified Eagle's medium (DMEM), CnT-Prime epithelial 2D differentiation medium (CnT-PR), and a three-dimensional (3D)-TGP scaffold. In Phase II, tissues were transported in a TGP cocktail and the ECS. The cells were cultured in 2D-DMEM and 3D-TGP, quantified, and characterized by immunohistochemistry. Results: The cells in 3D-TGP culture maintained epithelial morphology in a better manner compared with 2D-DMEM, in which they developed fibroblast-like morphology. The TGP-transported cells grew rapidly. Immunohistochemical analysis results for AE1/AE3, EGFR, integrin-ß1, p63, and p75 were intensely positive in 3D-TGP. Conclusion: The TGP-based cocktail used in human buccal tissue transportation yielded cells with better morphology maintenance. The TGP scaffold provides an optimal in vitro environment wherein epithelial cells better maintain their native phenotype compared to those cultured through conventional methods. These results suggest using TGP for the transportation and culture of human buccal tissues for clinical applications. In addition, the use of a TGP-based cocktail for the transport of other tissues for regenerative medicine applications is worth further analysis.


Subject(s)
Tissue Engineering , Urethral Stricture , Cells, Cultured , Epithelial Cells , Humans , Polymers , Tissue Engineering/methods
3.
Biomed Pharmacother ; 145: 112243, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34840031

ABSTRACT

OBJECTIVE: In this pilot clinical study, we report the beneficial effects of beta glucans derived from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients. METHODS: A total of 24 RT-PCR positive COVID-19 patients were recruited and randomly divided into three groups (Gr): Gr. 1 control (n = 8) - Standard treatment; Gr. 2: Standard treatment + AFO-202 beta glucan (n = 8); and Gr. 3, Standard treatment + combination of AFO-202 and N-163 beta glucans (n = 8) for 30 days. RESULTS: There was no mortality or requirement of ventilation of the subjects in any of the groups. There was a decrease in D-Dimer values (751 ng/ml to 143.89 ng/ml) and IL-6 values (7.395-3.16 pg/ml) in Gr. 1 in 15 days but the levels increased to abnormal levels on day 30 (D-Dimer: 202.5 ng/ml; IL-6 55.37 pg/ml); which steadily decreased up to day 30 in groups 2 (D-dimer: 560.99 ng/dl to 79.615; IL-6: 26.18-3.41 pg/ml) and 3 (D-dimer: 1614 ng/dl to 164.25 ng/dl; IL-6: 6.25-0.5 pg/ml). The same trend was observed with ESR. LCR and LeCR increased while NLR decreased significantly in Gr. 3. CD4 + and CD8 + T cell count showed relatively higher increase in Gr.3. There was no difference in CRP within the groups. CONCLUSION: As these beta glucans are well known food supplements with a track record for safety, larger multi-centric clinical studies are recommended to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.


Subject(s)
Aureobasidium , COVID-19 Drug Treatment , COVID-19 , Cytokine Release Syndrome , Fibrin Fibrinogen Degradation Products/analysis , Interleukin-6/analysis , beta-Glucans/administration & dosage , Biomarkers/blood , COVID-19/blood , COVID-19/diagnosis , Complementary Therapies/methods , Cytokine Release Syndrome/blood , Cytokine Release Syndrome/etiology , Cytokine Release Syndrome/prevention & control , Dietary Supplements , Female , Humans , Immunologic Factors/administration & dosage , Male , Middle Aged , Pilot Projects , SARS-CoV-2 , Treatment Outcome
4.
Tokai J Exp Clin Med ; 46(1): 1-6, 2021 Apr 20.
Article in English | MEDLINE | ID: mdl-33835468

ABSTRACT

BACKGROUND: Buccal mucosal epithelial cells show promising application for various regenerative medicine approaches. In this study, we examined the feasibility of culturing rabbit and human buccal mucosal epithelial cells in a novel thermoreversible gelation polymer (TGP) scaffold, without feeder layers or other foreign proteins. METHODS & RESULTS: The results of this 28-day in vitro culture, u sing the conventional technique (2D) and TGP (3D) showed that the epithelial cell morphology could be maintained only in the TGP group while cells in the 2D group de-differentiated to fibroblast morphology in both human and rabbit samples. CK3 expression, a marker for epithelial differentiation was higher in 3D-TGP cultured cells than 2D. CONCLUSION: TGP based in vitro cell culture is a prospective methodology to culture buccal mucosal epithelial cells efficiently without using foreign biological components for tissue engineering applications.


Subject(s)
Cell Culture Techniques , Cell- and Tissue-Based Therapy , Epithelial Cells/physiology , Mouth Mucosa/cytology , Polymers , Tissue Engineering/methods , Tissue Scaffolds , Animals , Cell Differentiation/genetics , Cells, Cultured , Epithelial Cells/metabolism , Feasibility Studies , Fibroblasts , Gene Expression , Humans , Keratin-3/genetics , Keratin-3/metabolism , Rabbits , Time Factors
5.
Front Immunol ; 11: 1548, 2020.
Article in English | MEDLINE | ID: mdl-32733487

ABSTRACT

Background: The COVID-19 pandemic has been causing varying severities of illness. Some are asymptomatic and some develop severe disease leading to mortality across ages. This contrast triggered us explore the causes, with the background that a vaccine for effective immunization or a drug to tackle COVID-19 is not too close to reality. We have discussed strategies to combat COVID-19 through immune enhancement, using simple measures including nutritional supplements. Discussion: A literature search on mortality-related comorbid conditions was performed. For those conditions, we analyzed the pro-inflammatory cytokines, which could cause the draining of the immune reservoir. We also analyzed the immune markers necessary for the defense mechanism/immune surveillance against COVID-19, especially through simple means including immune enhancing nutritional supplement consumption, and we suggest strategies to combat COVID-19. Major comorbid conditions associated with increased mortality include cardiovascular disease (CVD), diabetes, being immunocompromised by cancer, and severe kidney disease with a senile immune system. Consumption of Aureobasidium pullulans strain (AFO-202) beta 1,3-1,6 glucan supported enhanced IL-8, sFAS macrophage activity, and NK cells' cytotoxicity, which are major defense mechanisms against viral infection. Conclusion: People with co-morbid conditions who are more prone to COVID-19-related deaths due to immune dysregulation are likely to benefit from consuming nutritional supplements that enhance the immune system. We recommend clinical studies to validate AFO-202 beta glucan in COVID-19 patients to prove its efficacy in overcoming a hyper-inflammation status, thus reducing the mortality, until a definite vaccine is made available.


Subject(s)
Betacoronavirus , Cardiovascular Diseases/epidemiology , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Diabetes Mellitus/epidemiology , Dietary Supplements , Neoplasms/epidemiology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , Renal Insufficiency, Chronic/epidemiology , Actinobacteria/chemistry , Biomarkers/blood , COVID-19 , Cardiovascular Diseases/immunology , Comorbidity , Coronavirus Infections/diet therapy , Coronavirus Infections/mortality , Cytokines/blood , Diabetes Mellitus/immunology , Humans , Immunocompromised Host , Neoplasms/immunology , Pandemics , Pneumonia, Viral/diet therapy , Pneumonia, Viral/mortality , Renal Insufficiency, Chronic/immunology , SARS-CoV-2 , beta-Glucans/pharmacology , beta-Glucans/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...